某健胎中药致畸作用及对HSP70表达的影响  

Teratogenicity of the prescription of reinforcing kidney, replenishing Qi and activatting blood and effect on HSP70 expression in rats

作　　者：程建安[1] 哈建利[2] 陈国元[1] 邓菁[1] 鲁翠荣[1] 刘芸[1] 刘卫东[1] 

机构地区：[1]华中科技大学同济医学院公共卫生学院,武汉430030 [2]湖北职业技术学院医学系

出　　处：《卫生研究》2004年第2期185-188,共4页Journal of Hygiene Research

基　　金：国家自然科学基金资助项目 (No .39870 92 3)

摘　　要：目的　保证新药某健胎中药 (PAKRQAB)的临床用药安全 ,评价其毒理学和分子生物学效应。方法　设 3个剂量组 :6 0、12和 2 4g (kg·d) ,最高剂量相当于临床拟用量的 80倍 ,另设溶剂对照组和阳性对照组。于孕期 6～ 15d经口给予受试物 ,第 2 0天检查对孕鼠和胎鼠的毒性和致畸性 ,并用WesternBlot方法测定孕鼠和胎鼠肝组织HSP70水平。结果　 3个健胎液剂量组均未诱发畸形 ,但高剂量组妊娠率下降 ,与阴性对照组比较差异有显著性 (P <0 0 5 )。孕鼠各剂量组HSP70表达与阴性对照组比较有不同程度的降低 ,对胎鼠HSP70表达影响不明显 ,孕鼠表达量较胎鼠高。结论　该健胎中药无致畸性 ,无母体毒性及发育毒性 。Objective To assess the safety of the Prescription of Reinforcing Kidney Replenishing Qi and Activating Blood (PAKRQAB) on the reproduction and development of rats. Methods The animals were divided into negative control, positive control and three experiment groups. PAKRQAB was administered by gavages during gestation day 6 to day 15 in doses of 60,12 and 2 4g/(kg·d), respectively. The body weight gain of pregnant rats, the body weight, body length and tail length of living fetuses and some other parameters of embryonic development were measured. Western Blot was used to detect the HSP70 level in liver tissue of pregnant rat and fetuses. Results Malformation of external and internal organ and of bone was not found in fetuses treated with PAKRQAB. But the rate of cyesis descended in the high dosage. The expression level of HSP70 in each dose group is significantly different than negative control group on pregnant rats, but fetuses this effect is not so significant. Conclusion PAKRQAB does not induce deformity or developmental toxicity. It's safe for pregnant rats though it may influence pregnancy rate when it is used in high dose.

关 键 词：胚胎毒性 致畸试验 HSP70 

分 类 号：R285.6[医药卫生—中药学] R977.9[医药卫生—中医学]